Result of AGM

August 8, 2017

Akers Biosciences, Inc.

Result of Annual General Meeting

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that, at the Company's Annual General Meeting held yesterday in Philadelphia, PA, all resolutions were passed.

Among the proposals (as announced on July 14, 2017) shareholders elected three new non-executive directors to the Board, Bill J. White, Richard C. Tarbox III and Christopher C. Schreiber; together with John J. Gormally, the Company's Chief Executive Officer and Raymond F. Akers Jr., Ph.D, the Company's Vice Chairman and Chief Scientific Director.

Thomas J. Knox, the previous Non-executive Chairman of the Company; together with Robert E. Andrews, Brandon Knox and Raza Bokhari, all non-executive directors of the Company, did not stand for re-election and have retired from the Board of directors with immediate effect.

Raymond F. Akers Jr., Ph.D., who, it is expected, will become Executive Chairman of Akers Bio following the next Board meeting of the Company, commented:

"I am delighted that Bill, Richard and Chris have joined the Board as non-executive directors. They are highly experienced within their respective fields and bring a diverse and relevant skillset to Akers Bio as we move into our next phase of growth and product commercialization.

"I am equally pleased to welcome John to the Board after his significant and continuing contribution as Chief Executive Officer of Akers Bio for the past year and a half. The impact John is making on the business is particularly evident in the increasing traction of our flagship rapid test for an allergic reaction to the widely-used blood-thinner, heparin.

"I would like finally to place on record again the Board's thanks to the outgoing directors for their significant contributions to the development of the Company and wish them well for the future."

All relevant disclosures required in accordance with Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the newly appointed directors were contained in the July 14, 2017 announcement.

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For more information:

Akers Biosciences, Inc.

John J. Gormally, Chief Executive Officer

Raymond F. Akers, Jr. PhD, Vice Chairman & Chief Scientific Director

Tel. +1 856 848 8698

finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. +44 (0)20 7220 0500

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7830 9704

Email: akers@vigocomms.com